(Q37997880)

26 August 2017

title

Modern haemophilia care (English)

1 reference

26 August 2017

0 references

Erik Berntorp

1

1 reference

26 August 2017

Amy D Shapiro

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

27 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

379

1 reference

26 August 2017

issue

9824

1 reference

26 August 2017

page(s)

1447-1456

1 reference

A study of variations in the reported haemophilia A prevalence around the world

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

The history of haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Genotype analysis identifies the cause of the "royal disease"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Blood-induced joint damage in hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Christmas disease: a condition previously mistaken for haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

The hemophilias--from royal genes to gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Coagulation factor concentrates: past, present, and future.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

1 reference

7 January 2021

Role of fibrin sealants in surgical procedures on patients with hemostatic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Surgery for hemophilia in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Dose and response in haemophilia--optimization of factor replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Changing pattern of care of boys with haemophilia in western European centres

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prophylaxis in haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Aspects of haemophilia prophylaxis in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Experience of prophylaxis treatment in children with severe haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Recent developments in clinimetric instruments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Reliability and construct validity of the compatible MRI scoring system for evaluation of haemophilic knees and ankles of haemophilic children. Expert MRI working group of the international prophylaxis study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Co-morbidities and quality of life in elderly persons with haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

How I treat age-related morbidities in elderly persons with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prolonged in-vivo half-life of factor VIIa by fusion to albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prolonged activity of factor IX as a monomeric Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Overview of inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Quantitation of anti-factor VIII antibodies in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Anaphylaxis in patients with congenital bleeding disorders and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Inhibitors of factor VIII in black patients with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Inhibitor development in correlation to factor VIII genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Tolerance, danger, and the extended family

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Cutting Edge Commentary: A Copernican Revolution? Doubts About the Danger Theory

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Immune tolerance induction in hemophilia A: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Systematic review of the management of patients with haemophilia A and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Role of von Willebrand factor in immune tolerance induction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

The international immune tolerance study: a multicenter prospective randomized trial in progress

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Surgery in haemophilic patients with inhibitor: 20 years of experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Surgery in patients with hemophilia and inhibitors: a review of the Norwegian experience with FEIBA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

A retrospective postlicensure survey of FEIBA efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Experiences in the prevention of arthropathy in haemophila patients with inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Transgenic pigs produce functional human factor VIII in milk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Alternative strategies for gene therapy of hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Outcome of liver transplantation for haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Factor replacement therapy in haemophilia--are there models for developing countries?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961139-2

7 January 2021

10.1016/S0140-6736(11)61139-2

Identifiers

DOI

1 reference

26 August 2017

1 reference